Supplementary materials - Pharmacogenetic testing in pediatric neurology: a pragmatic study evaluating clinician and patient perceptions

The Pharmacy Practice Research Unit funded the 26 pharmacogenetic tests used for this study (a $200 value per test). The funding source had no involvement in study design, collection, analyses or interpretation of data. MA Pe´pin, AS Otis, Z Tremblay, M Boule´ andMEMe´ tras received a Precision Rx test fromDynacare ($200 value)with the objective to better understand the pharmacogenetic testing process for the present study. D Lebel is a member of the Executive Steering Committee of the federal and provincial grant funded Canadian Pharmacogenomics Network for Drug Safety. B Carleton received a grant from the Genomic Applications Partnership Program from Genome Canada which required an industry partner (Dynacare Next) and is a clinical advisor to this company. B Carleton is on the Pharmacogenomics Advisory Board of United Health Group (Minneapolis, USA). JF Bussie` res received a grant from the Canadian Pharmacogenomics Network for Drug Safety to support pharmacogenomic research (recruitment and enrolment of patients, characterization of patient-specific drug outcomes and validation of clinical data).